Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

OMF-geförderte Forschung: Verformbarkeit roter Blutkörperchen bei ME / CFS

In diesem OMFScienceWednesday präsentieren wir ein neues Projekt, das von OMF finanziert wird und das die „Verformbarkeit“ von roten Blutkörperchen als potenziellen Biomarker für ME / CFS bewerten wird.

Rote Blutkörperchen (RBCs) sind die häufigsten Zellen im Blut. Ihre Hauptaufgabe besteht darin, Sauerstoff und Kohlendioxid im Blut zu transportieren. Diese Rolle hängt teilweise von ihrer „Verformbarkeit“ / Elastizität ab, wenn sie durch kleine Blutgefäße fließen. Veränderungen der RBC-Verformbarkeit wurden mit Entzündungen und Krankheiten wie Sepsis in Verbindung gebracht, und einige Studien legen nahe, dass RBC-Schäden bei ME / CFS auftreten. Diese Beobachtungen, zusammen mit einer neuen Technologie zur Messung der RBC-Verformbarkeit veranlassten das Team von Dr. Ron Davis in Stanford und ihre Mitarbeiter an der San Jose State University, die Erythrozytenverformbarkeit in ME / CFS zu untersuchen.

In einigen sehr frühen Daten, die von diesem Team generiert wurden, gibt es Hinweise, dass die RBC-Verformbarkeit bei einigen ME / CFS-Patienten reduziert ist. Die bisher getesteten ME / CFS-Erythrozyten scheinen sich langsamer zu bewegen und weniger zu erneuern als als gesunde Kontrollen, wie Tests mit dieser neuen Technologie zeigen. Wir finanzieren ein Projekt, um diese Ergebnisse bei weiteren Patienten zu bestätigen und die Erythrozyten mit zusätzlichen Methoden zu untersuchen, einschließlich verschiedener Arten von fortgeschrittener Mikroskopie, um besser zu verstehen, warum diese Unterschiede bestehen.

Wenn diese Experimente erfolgreich sind, können sie einen neuen Biomarker für ME / CFS etablieren, der bei der Diagnose helfen und möglicherweise neue Behandlungen finden kann! Bleib Sie dran für mehr Informationen!

Erfahren Sie mehr über RBCs in diesem Khan Academy Video:


Vielen Dank an Anita für die Übersetzung.

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.


In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.


The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers‘ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.


About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of six prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.


Heather Ah San

Development and Communications Manager